PMC:7228307 / 842-1253 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"20","span":{"begin":98,"end":102},"obj":"Gene"},{"id":"23","span":{"begin":347,"end":394},"obj":"Species"},{"id":"24","span":{"begin":396,"end":406},"obj":"Species"},{"id":"27","span":{"begin":285,"end":292},"obj":"Disease"},{"id":"28","span":{"begin":294,"end":315},"obj":"Disease"},{"id":"29","span":{"begin":328,"end":338},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"Gene:2213"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"Tax:2697049"},{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"Tax:2697049"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"MESH:D009369"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"MESH:D007249"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) req"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T7","span":{"begin":3,"end":12},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) req"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T3","span":{"begin":294,"end":315},"obj":"Disease"},{"id":"T4","span":{"begin":328,"end":338},"obj":"Disease"},{"id":"T5","span":{"begin":347,"end":394},"obj":"Disease"},{"id":"T6","span":{"begin":347,"end":380},"obj":"Disease"},{"id":"T7","span":{"begin":396,"end":400},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) req"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T11","span":{"begin":55,"end":58},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T12","span":{"begin":73,"end":74},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T13","span":{"begin":98,"end":100},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) req"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T6","span":{"begin":307,"end":315},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"},{"id":"T7","span":{"begin":328,"end":338},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"}],"text":"as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) req"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"20","span":{"begin":98,"end":102},"obj":"Gene"},{"id":"23","span":{"begin":347,"end":394},"obj":"Species"},{"id":"24","span":{"begin":396,"end":406},"obj":"Species"},{"id":"27","span":{"begin":285,"end":292},"obj":"Disease"},{"id":"28","span":{"begin":294,"end":315},"obj":"Disease"},{"id":"29","span":{"begin":328,"end":338},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"pubann:denotes","subj":"20","obj":"Gene:2213"},{"id":"A23","pred":"pubann:denotes","subj":"23","obj":"Tax:2697049"},{"id":"A24","pred":"pubann:denotes","subj":"24","obj":"Tax:2697049"},{"id":"A27","pred":"pubann:denotes","subj":"27","obj":"MESH:D009369"},{"id":"A28","pred":"pubann:denotes","subj":"28","obj":"MESH:D007249"},{"id":"A29","pred":"pubann:denotes","subj":"29","obj":"MESH:D007239"}],"text":"as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) req"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T2","span":{"begin":347,"end":394},"obj":"Species"},{"id":"T3","span":{"begin":396,"end":406},"obj":"Species"}],"attributes":[{"id":"A2","pred":"ncbi_taxonomy_id","subj":"T2","obj":"NCBItxid:2697049"},{"id":"A3","pred":"ncbi_taxonomy_id","subj":"T3","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) req"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T9","span":{"begin":27,"end":243},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) req"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T7","span":{"begin":3,"end":12},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) req"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T2","span":{"begin":294,"end":315},"obj":"Disease"},{"id":"T3","span":{"begin":328,"end":338},"obj":"Disease"},{"id":"T4","span":{"begin":347,"end":394},"obj":"Disease"},{"id":"T5","span":{"begin":396,"end":406},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) req"}

{"project":"LitCovid-sentences","denotations":[{"id":"T9","span":{"begin":27,"end":243},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"as cytokines or other Igs. The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) req"}